FDA WARNING_LETTER - Usine Rotec Inc - August 30, 2012

The FDA issued a Warning Letter to Usine Rotec International, Inc. following an inspection from August 27-30, 2012, which found their patient beds to be adulterated and misbranded. The inspection revealed significant deviations from the Quality System (QS) regulation (21 CFR Part 820) and Medical Device Reporting (MDR) requirements (21 CFR Part 803). Key QS violations included failures to establish and maintain adequate procedures for design validation, corrective and preventive actions (CAPA), complaint handling, design reviews, design verification, documentation of acceptance activities, quality audits, device history records (DHRs), and document control. Additionally, the firm's devices were misbranded due to a failure to adequately develop, maintain, and implement written MDR procedures. The firm's responses were deemed inadequate, often lacking evidence of completed corrective actions or systemic retrospective reviews. The FDA requires a written response within 15 business days detailing specific corrections, preventive actions, and a timetable. Failure to correct these violations could impact federal contracts, premarket approvals for Class III devices, and Certificates to Foreign Governments. The letter emphasizes the need for a thorough investigation into the root causes of these systemic quality management issues.